ASX Release: 23 January 2023 Melbourne, Australia; Acrux Limited (ASX:ACR) Link Here: Acrux today announced that it has concluded an agreement with Gedeon Richter Plc., one of its manufacturing and distribution partners, for Gedeon Richter to buy out the future royalties of Lenzetto® for contracted territories for EUR4.10 million, which at current rates of exchange […]
Melbourne, Australia – 8 August 2022 Link here : Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has accepted for review Acrux’s application for a generic version (Abbreviated New Drug Application or ‘ANDA’) of cold sore treatment, Acyclovir Cream, 5%. Key Highlights Acrux has […]
Biomedical projects at the cutting edge of innovation will receive a $25m cash injection, in a boost for next-gen medicine including stem cell research, new treatments for autism and a technology that allows medicine to be taken through the skin. The $25m investment through the federal Biomedical Translation Fund will potentially benefit thousands of Australians […]
Melbourne, Australia; 28 July 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic version of EMLA® (Lidocaine 2.5% and Prilocaine 2.5%) Cream. In June 2019, Acrux submitted an ANDA to seek approval from the FDA to market its generic version […]
Melbourne, Australia; 22 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has granted approval of the Company’s generic version of Jublia® (efinaconazole) topical solution, 10%. Key Points FDA’s approval of the application represents an important milestone for Acrux, being its second approval […]
Melbourne, Australia; 8 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) today announced that Almirall LLC has initiated patent litigation against Acrux in the U.S. District Court for the District of New Jersey, regarding the Company’s Paragraph IV Abbreviated New Drug Application (ANDA) for Dapsone Gel 7.5% (a generic version of Aczone® Gel, 7.5%), […]
Melbourne, Australia; 4 June 2021: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce Mr Don Brumley has joined the Board as a Non-executive Director. Mr Brumley has 30 years’ experience as a senior partner of Ernst & Young, Oceania. He has extensive experience in IPOs, transactions and audit. Mr Brumley has advised […]
Link to Full Article Melbourne, Australia; 31 May 2021: As announced on 30 April 2021 Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to confirm that the Company’s 100% owned investee company Acrux Pharma Pty Ltd has received approval from AusIndustry for an Advance and Overseas Finding application. The finding covers financial years 2018/19, […]
Link to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]
Link to Full Article Acrux (ACR) has wrapped up a share purchase plan that was more than seven times oversubscribed after receiving approximately $15.1 million in applications The placement has since been scaled back to roughly $9.9 million, but still marks a significant increase on the $2 million it was initially seeking ACR says funds […]